Literature DB >> 29744343

Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario.

Luca Viganò1,2, Ana Lleo2,3, Alessio Aghemo2,3.   

Abstract

Entities:  

Year:  2018        PMID： 29744343      PMCID： PMC5934139          DOI： 10.21037/hbsn.2018.01.01

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  17 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

Review 2.  Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.

Authors:  Elisabetta Degasperi; Massimo Colombo
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09-08

3.  Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC.

Authors:  Luca Viganò; Simone Conci; Matteo Cescon; Cristina Fava; Paola Capelli; Antonietta D'Errico; Guido Torzilli; Luca Di Tommaso; Felice Giuliante; Fabio Maria Vecchio; Mauro Salizzoni; Ezio David; Antonio Daniele Pinna; Alfredo Guglielmi; Lorenzo Capussotti
Journal:  J Hepatol       Date:  2015-01-31       Impact factor: 25.083

4.  Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.

Authors:  M J Contos; W Cales; R K Sterling; V A Luketic; M L Shiffman; A S Mills; R A Fisher; J Ham; A J Sanyal
Journal:  Liver Transpl       Date:  2001-04       Impact factor: 5.799

5.  Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis.

Authors:  Neil H Bhayani; Omar Hyder; Wayne Frederick; Richard D Schulick; Christopher L Wolgang; Kenzo Hirose; Barish Edil; Joseph M Herman; Michael A Choti; Timothy M Pawlik
Journal:  Surgery       Date:  2012-08       Impact factor: 3.982

6.  Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.

Authors:  F Cauchy; S Zalinski; S Dokmak; D Fuks; O Farges; L Castera; V Paradis; J Belghiti
Journal:  Br J Surg       Date:  2012-11-12       Impact factor: 6.939

7.  Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

Authors:  Kavita Bhalla; Bor Jang Hwang; Ruby E Dewi; William Twaddel; Olga G Goloubeva; Kwok-Kin Wong; Neeraj K Saxena; Shyam Biswal; Geoffrey D Girnun
Journal:  Cancer Prev Res (Phila)       Date:  2012-03-31

8.  Statin use and non-alcoholic steatohepatitis in at risk individuals.

Authors:  Paola Dongiovanni; Salvatore Petta; Ville Mannisto; Rosellina Margherita Mancina; Rosaria Pipitone; Vesa Karja; Marco Maggioni; Pirjo Kakela; Olov Wiklund; Enrico Mozzi; Stefania Grimaudo; Dorota Kaminska; Raffaela Rametta; Antonio Craxi; Silvia Fargion; Valerio Nobili; Stefano Romeo; Jussi Pihlajamaki; Luca Valenti
Journal:  J Hepatol       Date:  2015-05-14       Impact factor: 25.083

9.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Authors:  Guillaume Lassailly; Robert Caiazzo; David Buob; Marie Pigeyre; Hélène Verkindt; Julien Labreuche; Violeta Raverdy; Emmanuelle Leteurtre; Sébastien Dharancy; Alexandre Louvet; Monique Romon; Alain Duhamel; François Pattou; Philippe Mathurin
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

10.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425
View more
  7 in total

Review 1.  Portal pressure monitoring-state-of-the-art and future perspective.

Authors:  Gang Xu; Fei Li; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-10

2.  Letter to the Editor: Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome.

Authors:  Gang Xu; Xiao-Xiang Zhou; Wei-Yu Xu; Yi-Lei Mao
Journal:  World J Surg       Date:  2020-03       Impact factor: 3.352

3.  Liver resection for multifocal hepatocellular carcinoma: is it an option?

Authors:  Luca Viganò; Guido Costa; Luca Di Tommaso
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

4.  c-Met Signaling Protects from Nonalcoholic Steatohepatitis- (NASH-) Induced Fibrosis in Different Liver Cell Types.

Authors:  Hannah K Drescher; Fabienne Schumacher; Teresa Schenker; Maike Baues; Twan Lammers; Thomas Hieronymus; Christian Trautwein; Konrad L Streetz; Daniela C Kroy
Journal:  Oxid Med Cell Longev       Date:  2018-11-12       Impact factor: 6.543

Review 5.  RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Kamyar Asadipooya; Kamran B Lankarani; Rishi Raj; Mohammadreza Kalantarhormozi
Journal:  Int J Endocrinol       Date:  2019-09-18       Impact factor: 3.257

6.  Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease.

Authors:  Yuting Ma; Guangdong Zhang; Zenggguang Kuang; Qian Xu; Tongtong Ye; Xue Li; Na Qu; Fang Han; Chengxia Kan; Xiaodong Sun
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

7.  In situ visualization of peroxisomal viscosity in the liver of mice with non-alcoholic fatty liver disease by near-infrared fluorescence and photoacoustic imaging.

Authors:  Yongqing Zhou; Ping Li; Xin Wang; Chuanchen Wu; Nannan Fan; Xiaoning Liu; Lijie Wu; Wei Zhang; Wen Zhang; Zhenzhen Liu; Bo Tang
Journal:  Chem Sci       Date:  2020-10-06       Impact factor: 9.825
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.